Phase IIA Double-Masked Randomized Sham-Controlled Trial of QPI-1007 Delivered by a Single Intravitreal Injection to Subjects With Acute Primary Angle-Closure Glaucoma (APACG)

This study is currently recruiting participants. (see Contacts and Locations)
Verified May 2014 by Quark Pharmaceuticals
Sponsor:
Information provided by (Responsible Party):
Quark Pharmaceuticals
ClinicalTrials.gov Identifier:
NCT01965106
First received: September 11, 2013
Last updated: May 21, 2014
Last verified: May 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: July 2015
  Estimated Primary Completion Date: December 2014 (Final data collection date for primary outcome measure)